• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

New Wave Subsidiary, N2 Logics Enters Partnership Agreement with Toronto-Based Naturopathic Doctor, Dr. Elizabeth Goldspink, to Collaborate on…

Microdose by Microdose
March 11, 2021
in Press Releases
Reading Time: 6 mins read
A A

TORONTO, March 11, 2021 /CNW/ – NEW WAVE HOLDINGS CORP. (the “Company” or “New Wave”) (CSE: SPOR) (FWB: 0XM2) (OTCPK: TRMNF) an
investment issuer that provides capital and support services, announces that N2 Logics Inc. (“N2”), an entity in which New Wave owns a significant interest, has signed an agreement to work alongside
Dr. Elizabeth Goldspink on multiple upcoming ventures.

Following the partnership agreement commencing on March 22nd, 2021, N2 Logics and Dr. Goldspink are set to collaborate on several developments in the upcoming months.
The e-commerce and digital marketing company plans to roll out its own line of functional mushroom products in the UK before this summer, which are currently being developed by Dr. Goldspink. N2
Logics is anticipating positive sales growth with the addition of this mushroom collection to its existing products, with a 18% increase in projected revenue following its launch.

As part of the partnership, N2 Logics will be using their Bloom Botanics brand to leverage sales of Dr. Goldspink’s Papillex & AHCC® by Papillex supplements via its ecommerce site and
Amazon. The recently announced Northern Ireland grace period extension will allow N2 Logics to streamline product distribution throughout the UK and across Europe from one location.

[bsa_pro_ad_space id=2]
ADVERTISEMENT

Dr. Goldspink is a Toronto-based Naturopathic Doctor and a prominent Health & Wellness Entrepreneur who is frequently featured as a wellness expert on CityTV’s
“CityLine”. Dr. Goldspink studied mind body medicine at Harvard Medical School, under Dr. Herbert Benson, MD, who is the world leader in the
study, advancement, and clinical practice of mind/body medicine. She writes for various print and online publications, including Integrative Healthcare Practitioners (IHP), and formulates natural
health products (NHP’s) for various innovative companies.

Continue on your trip...

AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush?

Enveric’s Latest Patent Signals a Clear Path Forward for PTSD Drug Development

Enveric’s EB-003 Shows Promise in PTSD Model, Offering a New Direction in Trauma Treatment

“We’re thrilled to be working with an accomplished and distinguished naturopathic doctor such as Dr. Elizabeth Goldspink,” commented Willie
Tsang
, CEO of New Wave. “She has a wealth of knowledge and experience in the natural health care and wellness sphere, and her expertise will contribute significantly to the growth and
development of our company as we continue to evolve. We look forward to working closely with her on a number of upcoming projects, which we’re confident will result in successful outcomes that will
be mutually beneficial.”

“Mushrooms are the future of wellness and I am excited to help make pure, transparent, and therapeutic blends accessible to the people who will benefit from them. I am looking forward to
collaborating with New Wave on multiple ventures,” said Dr. Elizabeth Goldspink.

ABOUT NEW WAVE HOLDINGS CORP.

New Wave Holdings Corp. (CSE: SPOR, FWB: 0XM2, OTCPK: TRMNF) is an investment issuer focused on the burgeoning nutraceutical and psychedelic sector and support for adaptive and progressive health
and wellness products and therapies. New Wave subsidiaries contain various health and beauty products within its portfolio of non-psychoactive plants and fungi as it continues to expand its product
distribution through vertical integration to provide end to end solutions while capturing a high margin business model.

Investors interested in connecting with New Wave Holdings can learn more about the company and contact the team at http://newwavecorp.com.

ABOUT Papillex™
Papillex™ is a company that offers a clinically-researched, nutrient-rich supplement that is designed to support the immune system in response to HPV. Papillex™
optimizes natural immunity and replaces key nutrients that have been found to be missing and low in people with persistent HPV symptoms.  Additionally, Papillex™ also offers a medicinal mushroom
product from the mycelium of shiitake mushrooms called AHCC®, which is backed by over 20 human clinical studies. AHCC® has been demonstrated to help the human body better respond to HPV and other
viral infections.

You can find out more at https://papillex.com

Order Reliable Lasix Now

ABOUT N2 LOGICS INC.
The N2 team brings over 10 years of experience in the field of online E-commerce and digital marketing, they utilize established and true methodologies to attract
high quality traffic online through lead generation and conversion optimization. Based on the current digital marketing needs, they focus on world class tactics and digital optimization to provide
return on investments. Uniquely positioned with New Wave, N2 will have the ability to grow globally while developing and discovery various products within the industry.

[bsa_pro_ad_space id=2]
ADVERTISEMENT

Investors interested in connecting with N2 can learn more about the company and contact the team at http://www.n2logics.com

ABOUT BLOOM BOTANICS E-COMMERCE PLATFORM
Bloom Botanics a highly innovative E-commerce platform that was formed when a collective of E-commerce experts from the UK, Ireland and the
North American Cannabis and Cannabis Accessory industry realised there was a significant opportunity to create Bloom Botanics to carry an impressive range of various of CBD and mushroom based
products and continue to aggressively increase its presence in this space from a product and geographical basis. The Bloom Botanics team currently consists of industry experts from 6 different
European countries and will be looking to expand that team and its expertise moving forward.

Investors interested in connecting with Bloom Botanics can learn more about the company and contact the team at https://bloombotanics.co.uk

Information relating to Bloom Botanics, contained in this news release was provided by Bloom Botanics and/or its agent and has not been independently verified by the Company. The Company does not
take responsibility for the accuracy of such information.

The CSE has not in any way passed on the merits of the Acquisition, and neither has approved nor disapproved the contents of this press release. Neither the CSE nor its Market Regulator (as that
term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. 

FORWARD-LOOKING INFORMATION DISCLAIMER

Certain statements contained in this news release may constitute forward–looking information, including but not limited to, applicable regulatory approval in connection with the Acquisition, the
closing of the Acquisition, expansion of operations, size and quality of future tournaments and projections regarding attendance at future events. Forward–looking information is often, but not
always, identified by the use of words such as “anticipate”, “plan”, “estimate”, “expect”, “may”, “will”, “intend”, “should”, and similar expressions. Forward–looking information involves known and
unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward–looking information. The Company’s actual results
could differ materially from those anticipated in this forward–looking information as a result of competitive factors and competition for investment opportunities, challenges relating to operations
in international markets, transaction execution risk, changes to the Company’s strategic growth plans, and other factors, many of which are beyond the control of the Company. The Company believes
that the expectations reflected in the forward–looking information are reasonable based on current expectations and potential investment pipeline, but no assurance can be given that these
expectations will prove to be correct and such forward–looking information should not be unduly relied upon. Any forward–looking information contained in this news release represents the
Company’s expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward–looking information whether
as a result of new information, future events or otherwise, except as required by applicable securities legislation.

Learn more about the psychedelics industry at Microdose.

Tags: New Wave Holdings
Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Next Post

Pure Extracts Sells First Shipment of Cannabis Oil Extracts to German Pharma Company

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.